Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPAM Systems Inc (EPAM) vs Invesco Ltd. (IVZ) Price & Performance

EPAM Systems IncTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

EPAM Systems Inc vs Invesco Ltd. — how do they compare? EPAM Systems Inc trades at $85.95 (market cap $4.49B), while Invesco Ltd. trades at $30.9 (market cap $13.43B). The key difference: Invesco Ltd. is far larger — about 3× EPAM Systems Inc's market cap, and Invesco Ltd. pays a 2.84% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.

EPAMIVZ
Market Cap
$4.49B$13.43B
Sector
TechnologyFinancials
52-Week High
$221.40$30.30
52-Week Low
$76.04$16.88
Enterprise Value
$3.74B$23.68B
Dividend Yield
2.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPAM Systems Inc

EPAM Systems trades at $87.22, up 3.22% today, with strong analyst support (65% buy ratings) and a consensus price target of $128.55 suggesting 47% upside. The stock shows attractive valuation metrics with P/E of 12.35 and P/S of 0.86, though technical indicators signal bearish momentum. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $2.86 exceeding expectations by $0.11. The company maintains solid profitability with 6.96% net margin and 10.93% ROE.

EPAM presents a compelling value opportunity with significant upside potential based on analyst targets, though near-term technical weakness and recent index reclassification from S&P 500 to SmallCap 600 create headwinds. The company's AI transformation expertise and strong client partnerships position it for growth, but investors should monitor execution risks and competitive pressures in the IT services sector.

Invesco Ltd.

Invesco (IVZ) trades at $28.73, up 1.16% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $30.50. Recent earnings show a mixed track record, with a Q1 2026 miss after two prior beats, while the company maintains strong operating cash flow of $1.53B in 2025 despite a negative net income margin. A dividend of $0.22 per share was declared for H1 2026, payable in June.

The outlook is cautiously optimistic, supported by analyst upgrades and solid cash generation, but profitability challenges and competitive pressures in asset management pose risks. Upside potential exists if the company returns to sustained earnings growth and meets Q2 2026 EPS expectations of $0.66.

Returns comparison

Trailing returns across standard periods

About EPAM Systems Inc

EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.

Read more on EPAM

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ